

PCT

ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C07D 471/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 99/15526 (43) International Publication Date: 1 April 1999 (01.04.99)</p>
<p>(21) International Application Number: PCT/EP98/05904 (22) International Filing Date: 15 September 1998 (15.09.98) (30) Priority Data: 9720052.1 19 September 1997 (19.09.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HARRINGTON, Frank, Peter [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: NOVEL COMPOUNDS</p> <div style="text-align: center; margin: 20px 0;"> <p style="text-align: right;">(I)</p> </div> <p>(57) Abstract</p> <p>N-(naphthyridinyl)-N'-phenyl-ureas/thioureas of general formula (I) are useful for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysesthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL COMPOUNDS

This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.

5


EP-A- 0556008 (Shionogi) discloses condensed imidazopyridine derivatives with psychotropic activity, including the compound 1,6-naphthyridine-6(5H)-carboxylic acid, 4-azido-3-[[[(1,1-dimethylethoxy) carbonyl] amino]-7,8-dihydro, ethyl ester.

- 10 WO96/39382 (Fujisawa) discloses the preparation of N-heterocycl-ureas as 5-HT antagonists, including the compound N-(1-methyl-1H-indol-5-yl)-N'-(1,2,3,4-tetrahydro-7-isoquinoliny)-urea.

It has now been surprisingly found that naphthyridinyl-urea compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).

30

Accordingly, the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:



35

(I)

where X is O or S

R¹ is hydrogen, phenylC₁₋₆ alkyl or C₁₋₆ alkyl;

- 5 R² is hydrogen or up to three substituents independently selected from halogen, NO₂, CN, N₃, C₁₋₆ alkylO-, C₁₋₆ alkylS-, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl-, C₁₋₆ alkenyl, C₁₋₆ alkynyl, C₁₋₆ haloalkylCO-, C₁₋₆ alkylCO-, C₃₋₆ cycloalkylCO-, C₃₋₆ cycloalkyl-C₁₋₄ alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, 10 phenyl-C₁₋₄ alkyl-, O-C₁₋₆ haloalkyl, CO₂C₁₋₄ alkyl, S(O)₂C₁₋₆ alkyl, C₁₋₄ alkylsulfamoyl or heterocyclyl, or -NR⁶R⁷ where R⁶ is hydrogen, C₁₋₄ alkyl or S(O)₂C₁₋₆ alkyl, and R⁷ is hydrogen, C₁₋₄ alkyl, -CHO, S(O)₂C₁₋₆ alkyl -CO₂C₁₋₄ alkyl or -COC₁₋₄ alkyl, 15 or an adjacent pair of R² groups together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.

The compounds of this invention are typically N-(tetrahydronaphthyridinyl), N'-optionally substituted phenyl-ureas or thioureas. Especially the compounds of the invention are 20 (tetrahydronaphthyridin-3-yl) ureas or thioureas. The phenyl moiety may be substituted by up to three, preferably 2 or 1, groups.

In the formula (I), alkyl groups, including alkyl groups that are part of another moiety, may be straight chain or branched. Aromatic rings, such as the aromatic ring in the 25 bicyclic heterocyclic moiety in formula (I) and phenyl groups, including phenyl groups that are part of other moieties, in R² may optionally be substituted with one or more independently selected substituents such as halogen or C₁₋₆ alkyl, C₁₋₆ alkoxy or C₁₋₆ alkylcarbonyl groups, or other optional substituents indicated below.

30 Suitable C₃₋₆ cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Suitable halo substituents include fluoro, chloro, iodo and bromo, which may also appear in haloalkyl, haloalkyloxy and haloalkyl carbonyl groups mentioned above, examples of 35 which are trifluoromethyl, trifluoromethoxy and trifluoroacetyl.

When any R² represents heterocyclyl, this group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated, for example containing

1, 2 or 3 heteroatoms selected from oxygen, nitrogen or sulphur, for example oxazolyl, thienyl or piperidinyl. The heterocyclyl group may contain up to 5, more preferably 1, 2 or 3 optional substituents.

- 5 Preferably a substituent for a heterocyclyl group is selected from halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, mono- and di-N-(C₁₋₆)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbonyl, aryloxy carbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl(C₁₋₆)alkyl.

- When an adjacent pair of R² together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring, it is preferably a 5- to 7-membered ring, which may be aromatic or non-aromatic. Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example, pyrrole or pyrrolidine. A carbocyclic or heterocyclic ring formed by an adjacent pair of R² together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one or more substituents, e.g. up to 3 substituents. Examples of suitable substituents for the carbocyclic or heterocyclic ring include; halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, mono- and di-N-(C₁₋₆)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbonyl, aryloxy carbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl(C₁₋₆)alkyl.

A suitable group of compounds of formula (I) have

R¹ as hydrogen, benzyl, methyl, ethyl, *iso*-propyl or *t*-butyl

R² as hydrogen, methyl, ethyl, *n*-butyl, *iso*-propyl, *t*-butyl, phenyl, benzyl,

30 methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, phenoxy,

benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl,

pivaloyl, *iso*-butyryl, benzoyl, trifluoromethyl, trifluoromethoxy,

trifluoroacetyl, carbomethoxy, carboethoxy, methylthio, *n*-propylsulfonyl,

isopropylsulfonyl, dimethylsulfamoyl or oxazolyl,

- 35 or two R² groups linked to form naphthyl, indolyl or indolinyl, optionally substituted by acetyl or methyl.

In a particular group of compounds of formula (I),

R¹ is hydrogen or methyl,

R² is hydrogen, methoxy, ethoxy, bromo, chloro, nitro, trifluoromethyl, or trifluoromethoxy.

Examples of compounds of formula (I) are:

- 5 N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridin-3-yl)-N'-(3-trifluoromethylphenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethoxyphenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-nitrophenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-methoxyphenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-bromophenyl)urea
10 N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethylphenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(phenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(5-chloro-2,4-dimethoxyphenyl)urea
N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-ethoxyphenyl)urea.

15

When synthesised, these compounds may be obtained in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in preparing pharmaceutically acceptable salts. The compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this
20 invention.

The above-listed compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, form a preferred aspect of the present invention.

25

Where compounds of the present invention possess chiral centres and as such may exist in different enantiomeric forms, the present invention extends to each enantiomeric form and mixtures thereof including diastereoisomers and racemates.

- 30 The compounds of this invention possess anti-convulsant activity and are therefore believed to be useful for administration to mammals in the treatment and/or prevention of the disorders mentioned above, especially for humans, but also as a veterinary treatment. The administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration.

35

An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50,

100, 200, 300 and 400 mg of the active compound. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately
5 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.

It is greatly preferred that the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.

10

Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are
15 preferred, in particular shaped oral compositions, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents,
20 lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as
25 sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the
30 active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for
35 reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example,

almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

- 5 Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can
10 be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

15 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the
20 compound of the invention.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

- 25 Accordingly, in a further aspect, the present invention provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with
30 anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's
35 syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS), which comprises a compound of formula (I), or a

pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.


The present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS), comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.

In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).


In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or

aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).

Another aspect of the invention provides a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (II)



where R^{1A} is R^1 as defined for formula (I) or a group convertible to R^1 , and
 P is NH_2 or NCX , X being as defined for formula (I),
 with a compound of formula (III)




where Q is NCX or NH_2 and different from P, X being as defined for formula (I), and
 R^{2A} is R^2 as defined for formula (I) or a group or groups convertible to R^2 ,
 and where required converting a R^{1A} or R^{2A} group to a R^1 or R^2 group, converting one R^1 or R^2 group to another R^1 or R^2 group, converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.

Conventional conditions for condensation of isocyanates or isothiocyanates with amines may be used, for example treatment in an inert solvent such as toluene, DMF or dichloromethane at ambient or elevated temperature.


- 5 Conversions of an R^{1A} or R^{2A} group to a R^1 or R^2 group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below. Interconversion of one R^1 or R^2 group to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more
10 complex or reactive substituent at the end of a synthetic sequence.

Compounds of formula (II) in which P is NH_2 may be prepared starting from a compound of formula (IV), such as a dinitro-1-methyl-2-pyridone



(IV)

by reaction with a compound of formula (V)




V)

25 in a solution of ammonia in a suitable solvent such as methanol, to obtain a compound of formula (VI) using a procedure similar to that of s Takada et al, J Med Chem, 1996, 39, 2844.

30

10



Compounds of formula (VI) may be converted to compounds of formula (II) by
5 hydrogenation or reduction of the nitro group. For example, a compound of formula (VI) may be hydrogenated by treatment with hydrogen in a suitable solvent such as methanol in the presence of a palladium/carbon catalyst. Alternatively, a compound of formula (VI) may be reduced with stannous chloride in concentrated hydrochloric acid in a suitable solvent such as ethanol.

10

Compounds of formula (IV) may be prepared using the procedure of E. Matsumura, M. Ariga and Y. Tohda, Bull. Chem. Soc. Japan, 52 (8), 2413-2419 (1979).

Compounds of formula (III) in which Q is iso(thio)cyanate are commercially available or
15 may be prepared by formation of iso(thio)cyanates from commercially available substituted phenyl compounds using conventional procedures such as described by I T Forbes *et al* , J. Med. Chem., 1993, 36, 1104, and in Fieser and Fieser, Reagents for Organic Synthesis Vol I. For example an isocyanate may be prepared by stirring a relevant amine with one equivalent of carboxyl diimidazole in a suitable solvent such as dichloromethane at room
20 temperature, and then evaporated to dryness *in vacuo*. Isothiocyanates may be prepared by reaction of the relevant amine with carbon disulphide in pyridine in the presence of dicyclohexylcarbodiimide.

Compounds of formula (II) in which P is iso(thio)cyanate may be similarly prepared
25 starting from the amines of formula (II) described above.

Compounds of formula (III) in which Q is NH₂ are commercially available or may be prepared by formation of amines on commercially available substituted phenyl compounds using conventional procedures.

30

Where intermediates disclosed for the above processes are novel compounds, they also form part of this invention.

The compounds of the present invention may contain a chiral centre, and therefore the
35 above processes may produce a mixture of diastereoisomers. A single diastereoisomer may

be prepared by separating such a mixture of diastereoisomers which has been synthesised using a racemic starting material, or by synthesis using an optically pure starting material.

The compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. When some of the compounds of this invention are allowed to crystallise or are recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. Similarly, some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. Crystallisation procedures will usually produce stoichiometric hydrates. Compounds containing variable amounts of water may be produced by processes such as lyophilisation.

The compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitable at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight. An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.

The present invention also includes pharmaceutically acceptable salts and derivatives of the compounds of the invention. Salt formation may be possible when one of the substituents carries an acidic or basic group. Salts may be prepared by salt exchange in conventional manner.

Acid-addition salts may be pharmaceutically acceptable or non-pharmaceutically acceptable. In the latter case, such salts may be useful for isolation and purification of the compound of the invention, or intermediates thereto, and will subsequently be converted into a pharmaceutically acceptable salt or the free base.

The preparation of compounds of formula (II) is illustrated by the following Descriptions; the preparation of compounds of this invention is illustrated by the following Examples. The utility of compounds of this invention is shown by the Pharmacological Data that follow the Examples.

Description 1

6-Benzyl-3-nitro-5,6,7,8-tetrahydro[1,6]naphthyridine

3,5-Dinitro-1-methyl-2-pyridone¹ (1.99g; 10 mmol) was added to a solution of ammonia in methanol (1.1M; 100ml; 110 mmol) and the resulting solution treated with 1-benzyl-4-piperidone (2.27g; 12 mmol). The resulting mixture was heated at 60°C for 5h, cooled to room temperature and evaporated to dryness under reduced pressure. The residue was
5 purified by chromatography through SiO₂ eluting with 50% ethyl acetate/60-80° petroleum ether to give the title compound (2.5g; 93%). Recrystallisation from ethyl acetate - 60 - 80° petroleum ether gave the title compound as a pale yellow, microcrystalline solid, mp 108°C;
10 (250MHz; CDCl₃) δ_H: 3.03 (2H, t, J = 6 Hz), 3.28 (2H, t, J = 6 Hz), 3.83 and 3.87 (each 2H, 2s), 7.38 - 7.49 (5H, m), 8.21 (1H, d, J = 2Hz), 9.33 (1H, d, J = 2 Hz)

1. E. Matsumura, M. Ariga and Y. Tohda, Bull. Chem. Soc. Japan, 52 (8), 2413-2419 (1979).

15

Description 2

3-Amino-6-benzyl-5,6,7,8-tetrahydro[1,6]naphthyridine

20 6-Benzyl-3-nitro-5,6,7,8-tetrahydro[1,6]naphthyridine (790mg; 2.93 mmol) was dissolved in ethanol (100ml), the solution heated at 50°C and treated with a solution of stannous chloride dihydrate (2.65g; 11.73 mmol) in conc. hydrochloric acid (10ml). After 10 min, the reaction mixture was concentrated under reduced pressure, neutralised by addition of 2M aqueous sodium hydroxide and extracted with DCM. The extracts were combined,
25 washed with water, saturated brine, dried (MgSO₄) and evaporated to dryness *in vacuo*. The brown residue was dissolved in methanol and SiO₂ added. The volatiles were removed under reduced pressure and the dried SiO₂ placed on the top of a silica column and subjected to chromatography, eluting with ethanol in ethyl acetate (0->20%) ethanol gradient. The title compound was obtained as a white powder (275mg; 39%).

30

(250MH, (CD₃)₂SO) δ_H: 2.33 (4H, br m), 3.25 (2H, s), 3.45 (2H, br s), 4.84 (2H, br s, exchangeable), 6.37 (1H, br s), 7.11 - 7.22 (5H, m), 7.56 (1H, br s)

Description 3

35

6-Methyl-3-nitro-5,6,7,8-tetrahydro[1,6]naphthyridine

3,5-Dinitro-1-methyl-2-pyridone (5.97g; 30 mmol) was treated with 1.22M ammonia in methanol (300ml) followed by 1-methyl-4-piperidone (3.73g, 33 mmol) and the mixture

heated at 60° for 5h, then allowed to stand at ambient temp for 72h. Evaporated to dryness under reduced pressure and the orange/red residue triturated under a mixture of dichloromethane and diethyl ether, collected by filtration, washed with diethyl ether and dried in air. Chromatography through silica gel, eluting with ethyl acetate, gave the title compound as a red solid (3.4g, 59%); ν_{\max} (CH_2Cl_2) 1530 and 1351 cm^{-1}

(250MHz; CDCl_3) δ_{H} : 2.53 (3H, s), 2.85 (2H, t, J = 6 Hz), 3.18 (2H, t, J = 6 Hz), 3.69 (2H, s), 8.14 (1H, d, J = 2 Hz), 9.23 (1H, d, J = 2 Hz)

10 Description 4

3-Amino-6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine

6-Methyl-3-nitro-5,6,7,8-tetrahydro[1,6]naphthyridine (2.72g, 1.41 mmol) was dissolved in methanol (100ml) and treated with 10% palladium on carbon (1.0g). The mixture was hydrogenated for 2h. The catalyst was removed by filtration through Celite, the filter bed washed with methanol and the filtrate evaporated to dryness under reduced pressure to give a yellow solid, which was triturated under diethyl ether and the solids collected by filtration, washed with diethyl ether and dried *in vacuo* (1.89g, 83%)

(250MHz, CDCl_3) δ_{H} : 2.46 (3H, s), 2.75 (2H, t, J = 6 Hz), 2.95 (2H, t, J = 6 Hz), 3.50 (2H, s), 3.56 (2H, br s, exchangeable), 6.65 (1H, d, J = 2 Hz), 7.92 (1H, d, J = 2 Hz)

Example 1

N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridin-3-yl)-N'-(3-trifluoromethylphenyl)urea, hydrochloride

3-Amino-6-methyl-5,6,7,8-tetrahydro-[1,6]-naphthyridine (163mg; 1 mmol) was dissolved in THF (20ml) and the solution treated with α,α,α -trifluoro-m-tolylisocyanate (187mg; 1 mmol). The resulting mixture was stirred at ambient temperature for 18h then evaporated to dryness under reduced pressure. The residual, brown solid was redissolved in THF (minimum volume) and the resulting solution treated with a solution of hydrogen chloride in diethyl ether (1.0M; 1ml; 1 mmol). This mixture was stirred at ambient temperature for 15 min. and the title compound collected by filtration, washed with THF and diethyl ether and dried under reduced pressure (366mg; 95%).

[250MHz; $(\text{CD}_3)_2\text{SO}$] δ_{H} : 2.84 (3H, br s); 2.90 - 3.30 (2H, m), 3.58 - 3.76 (2H, m), 4.20 - 4.40 (1H, m), 4.42 - 4.60 (1H, m), 7.21 - 7.27 (1H, m), 7.54 - 7.64 (2H, m), 7.78 - 7.81

(2H, m), 8.32 (1H, s, exchangeable), 8.46 (1H, d, J = 2 Hz), 9.90 (1H, s, exchangeable), 10.80 - 11.10 (1H, br s, exchangeable); m/z (API⁺): 351.1 [M+H]⁺

Example 2

5

N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethoxyphenyl)urea

The title compound was prepared in 82% yield from amine of Description 4 and 4-trifluoromethoxyphenyl isocyanate using a method similar to that of Example 1.

10

¹H NMR (250MHz, d⁶-DMSO) δ : 2.21 (3H, s), 2.53 (2H, t, J = 6 Hz), 2.68 (2H, t, J = 6 Hz), 3.34 (2H, s), 7.14 (2H, d, J = 9 Hz), 7.41 (2H, d, J = 9 Hz), 7.48 (1H, d, J = 2 Hz), 8.20 (1H, d, J = 2 Hz), 8.65 (1H, s), 8.84 (1H, s); m/z (API⁺): 367 (MH⁺; 33%).

15

Example 3

N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-nitrophenyl)urea

The title compound was prepared in 75% yield from amine of Description 4 and 3-nitrophenyl isocyanate using a method similar to that of Example 1.

20

¹H NMR (250MHz, d⁶-DMSO) δ : 2.23 (3H, s), 2.55 (2H, t, J = 6 Hz), 2.70 (2H, t, J = 6 Hz), 3.37 (2H, s), 7.44 (1H, t, J = 8 Hz), 7.53 (1H, d, J = 2 Hz), 7.60 (1H, dd, J = 2 and 8 Hz), 7.70 (1H, dd, J = 2 and 8 Hz), 8.24 (1H, d, J = 2 Hz), 8.43 (1H, t, J = 2 Hz), 8.79 (1H, s), 9.20 (1H, s); m/z (API⁺): 328 (MH⁺; 72%).

25

Example 4

N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-methoxyphenyl)urea

30

The title compound was prepared in 20% yield from amine of Description 4 and 3-methoxyphenyl isocyanate using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ : 2.68 (3H, s), 2.84 (2H, t, J = 6 Hz), 3.00 (2H, t, J = 6 Hz), 3.66 (2H, s), 3.90 (3H, s), 6.74 (1H, d, J = 8 Hz), 7.10 (1H, d, J = 8 Hz), 7.35 (2H, m), 7.82 (1H, s), 8.50 (1H, s), 8.90 (1H, s), 8.96 (1H, s); m/z (API⁺): 313 (MH⁺; 100%).

35

Example 5

N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-bromophenyl)urea

The title compound was prepared in 86% yield from amine of Description 4 and 3-bromophenyl isocyanate using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ: 2.47 (3H, s), 2.79 (2H, t, J = 6 Hz), 2.95 (2H, t, J = 6 Hz), 3.61 (2H, s), 7.24 - 7.48 (3H, bm), 7.76 (1H, d, J = 2 Hz), 7.98 (1H, t, J = 2 Hz), 8.47 (1H, d, J = 2 Hz), 8.95 (1H, s), 9.10 (1H, s); m/z (API⁺): 361, 363 (MH⁺; 43%)

Example 6**N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethylphenyl)urea**

The title compound was prepared in 65% yield from amine of Description 4 and 4-trifluoromethylphenyl isocyanate using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ: 2.35 (3H, s), 2.67 (2H, t, J = 6 Hz), 2.83 (2H, t, J = 6 Hz), 3.49 (2H, s), 7.59 - 7.72 (5H, bm), 8.37 (1H, d, J = 2 Hz), 8.88 (1H, s), 9.21 (1H, s); m/z (API⁺): 351 (MH⁺; 94%)

Example 7**N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(phenyl)urea**

The title compound was prepared in 74% yield from amine of Description 4 and phenyl isocyanate using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ: 2.30 (3H, s), 2.62 (2H, t, J = 6 Hz), 2.77 (2H, t, J = 6 Hz), 3.43 (2H, s), 6.92 (1H, t, J = 7 Hz), 7.23 (2H, dd, J = 7 and 8 Hz), 7.40 (2H, d, J = 8 Hz), 7.58 (1H, d, J = 2 Hz), 8.29 (1H, d, J = 2 Hz), 8.67 (1H, s), 8.70 (1H, s); m/z (API⁺): 283 (MH⁺; 75%)

Example 8**N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(5-chloro-2,4-dimethoxyphenyl)urea**

The title compound was prepared in 71% yield from amine of Description 4 and 5-chloro, 2,4-dimethoxyphenyl isocyanate using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ: 2.43 (3H, s), 2.75 (2H, t, J = 6 Hz), 2.90 (2H, t, J = 6 Hz), 3.57 (2H, s), 3.94 (3H, s), 4.01 (3H, s), 6.94 (1H, s), 7.72 (1H, d, J = 2 Hz), 8.20 (1H, s), 8.30 (1H, s), 8.38 (1H, d, J = 2 Hz), 9.37 (1H, s); m/z (API⁺): 377 (MH⁺; 100%)

Example 9

10 N-(6-Methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-ethoxyphenyl)urea

The title compound was prepared in 88% yield from amine D4 and 4-ethoxyphenyl isocyanate using a method similar to that of Example 1.

15 ¹H NMR (250MHz, d⁶-DMSO) δ: 1.15 (3H, t, J = 7 Hz), 2.20 (3H, s), 2.51 (2H, t, J = 6 Hz), 2.67 (2H, t, J = 6 Hz), 3.33 (2H, s), 3.82 (2H, q, J = 7 Hz), 6.70 (2H, d, J = 9 Hz), 7.19 (2H, d, J = 9 Hz), 7.47 (1H, d, J = 2 Hz), 8.18 (1H, d, J = 2 Hz), 8.40 (1H, s), 8.50 (1H, s); m/z (API⁺): 327 (MH⁺; 100%)

20

PHARMACOLOGICAL DATA

1. Binding Assay Method

25 WO 92/22293 (SmithKline Beecham) discloses compounds having anti-convulsant activity, including *inter alia* the compound *trans*-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham).
30 The affinity of test compounds to the novel receptor site is assessed as follows.

Method

Whole forebrain tissue is obtained from rats. The tissue is first homogenised in buffer
35 (usually 50mM Tris/HCl, pH 7.4). The homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.

To carry out the radioligand binding assay, aliquots of tissue prepared as above (usually at a concentration of 1-2mg protein/ml) are mixed with aliquots of [3H]-Compound A

dissolved in buffer. The final concentration of [3H]-Compound A in the mixture is usually 20nM. The mixture is incubated at room temperature for 1 hour. [3H]-Compound A bound to the tissue is then separated from unbound [3H]-Compound A by filtration through Whatman GF/B glass fibre filters. The filters are then washed rapidly with ice-cold buffer. The amount of radioactivity bound to the tissue trapped on the filters is measured by addition of liquid scintillation cocktail to the filters followed by counting in a liquid scintillation counter.

In order to determine the amount of "specific" binding of [3H]-Compound A, parallel assays are carried out as above in which [3H]-Compound A and tissue are incubated together in the presence of unlabelled Compound A (usually 3 μ M). The amount of binding of [3H]-Compound A remaining in the presence of this unlabelled compound is defined as "non-specific" binding. This amount is subtracted from the total amount of [3H]-Compound A binding (i.e. that present in the absence of unlabelled compound) to obtain the amount of "specific" binding of [3H]-Compound A to the novel site.

The affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested. The decrease in the level of specific [3H]-Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.

Results

Compounds of this invention were active in this test with pKi values greater than 6. For example, compounds of Examples 3-8 gave pKi values greater than 7.5.

2. MEST Test

The maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties¹. In this model, anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.

Method

Mice (naive male, Charles River, U.K. CD-1 strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with

various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC₅₀) of the mice in a particular treatment group is determined by the 'up and
5 down' method of Dixon and Mood (1948)². Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)³.

In control animals the CC₅₀ is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is
10 increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.

The percentage increase or decrease in CC₅₀ for each group compared to the control is calculated.

15

Studies are carried out using a Hugo Sachs Elektronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.

20 Drugs are suspended in 1% methyl cellulose.

References


1. Loscher, W. and Schmidt, D. (1988). *Epilepsy Res.*, 2, 145-181
- 25 2. Dixon, W.J. and Mood, A.M. (1948). *J. Amer. Stat. Assn.*, 43, 109-126
3. Litchfield, J.T. and Wilcoxon, F. (1949). *J. Pharmacol. exp. Ther.*, 96, 99-113

Results

- 30 Compounds of this invention dosed by the oral route as a suspension in methyl cellulose and tested one hour post dosing show an increase in seizure threshold. For example, at a dose of 10 mg/kg p.o. the compounds of Examples 3 and 7 showed statistically significant increases of 60% and 15% respectively.

CLAIMS

1. A compound of formula (I) or pharmaceutically acceptable salt thereof:



where X is O or S

10 R¹ is hydrogen, phenylC₁₋₆ alkyl or C₁₋₆ alkyl,

R² is hydrogen or up to three substituents independently selected from halogen,

NO₂, CN, N₃, C₁₋₆ alkylO-, C₁₋₆ alkylS-, C₁₋₆ alkyl, C₁₋₆ haloalkyl,

C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl-, C₁₋₆alkenyl, C₁₋₆alkynyl,

C₁₋₆haloalkylCO-, C₁₋₆alkylCO-, C₃₋₆cycloalkylCO-,

15 C₃₋₆cycloalkyl-C₁₋₄alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl,

phenyl-C₁₋₄alkyl-, O-C₁₋₆haloalkyl, CO₂C₁₋₄alkyl, S(O)₂C₁₋₆alkyl,

C₁₋₄alkylsulfamoyl or heterocyclyl, or -NR⁶R⁷ where

R⁶ is hydrogen, C₁₋₄ alkyl or S(O)₂C₁₋₆alkyl, and

R⁷ is hydrogen, C₁₋₄alkyl, -CHO, S(O)₂C₁₋₆alkyl -CO₂C₁₋₄alkyl or

20 -COC₁₋₄alkyl,

or an adjacent pair of R² groups together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.

2. A compound of formula (I) which is a (tetrahydronaphthyridin-3-yl) urea or
25 thiourea.

3. A compound of formula (I) in which

R¹ as hydrogen, benzyl, methyl, ethyl, *iso*-propyl or *t*-butyl

R² as hydrogen, methyl, ethyl, *n*-butyl, *iso*-propyl, *t*-butyl, phenyl, benzyl,

30 methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, phenoxy,

benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl,

pivaloyl, *iso*-butyryl, benzoyl, trifluoromethyl, trifluoromethoxy,


trifluoroacetyl, carbomethoxy, carboethoxy, methylthio, *n*-propylsulfonyl,

isopropylsulfonyl, dimethylsulfamoyl or oxazolyl,

35 R⁶ and R⁷ are hydrogen, acetyl or methanesulfonyl,


or two R² groups linked to form naphthyl, indolyl or indolynyl, optionally substituted by acetyl or methyl.

4. A compound of formula (I) in which
 - 5 R¹ is hydrogen or methyl,
 - R² is hydrogen or one or more of methoxy, ethoxy, bromo, chloro, nitro, trifluoromethyl or trifluoromethoxy.
5. A compound of formula (I) which is
 - 10 N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridin-3-yl)-N'-(3-trifluoromethylphenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethoxyphenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-nitrophenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-methoxyphenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(3-bromophenyl)urea
 - 15 N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-trifluoromethylphenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(phenyl)urea
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(5-chloro-2,4-dimethoxyphenyl)urea or
 - N-(6-methyl-5,6,7,8-tetrahydro[1,6]naphthyridine-3-yl)-N'-(4-ethoxyphenyl)urea.
 - 20
6. A process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (II)



- where R^{1A} is R¹ as defined for formula (I) or a group convertible to R¹, and
- 30 P is NH₂ or NCX, X being as defined for formula (I),

with a compound of formula (III)



where Q is NCX or NH₂ and different from P, X being as defined for formula (I), and

5 R^{2A} is R² as defined for formula (I) or a group or groups convertible to R²,
and where required converting a R^{1A} or R^{2A} group to a R¹ or R² group, converting one
R¹ or R² group to another R¹ or R² group, converting a salt product to the free base or
another pharmaceutically acceptable salt, or converting a free base product to a
pharmaceutically acceptable salt.

10


7. A pharmaceutical composition for use in the treatment and/or prophylaxis of
anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a
subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from
substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders
15 treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-
traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia,
Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea,
schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated
with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy),
20 tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia,
especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate
neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple
sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity),
temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS), which
25 comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, and a pharmaceutically acceptable carrier.

8. A method of treatment and/or prophylaxis of anxiety, mania, depression, panic
disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or
30 neural shock, the effects associated with withdrawal from substances of abuse such as
cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with
anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's
disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other
degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive
35 disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including
circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's
syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia,

neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS), comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.

9. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).

10. A compound of formula (I) or pharmaceutically acceptable salt thereof:



where R^1 is hydrogen, C_{1-6} alkyl, or phenyl- C_{1-6} alkyl.

R^2 is hydrogen or up to three substituents selected from halogen, CF_3 , NO_2 , CN , N_3 , C_{1-6} alkylo-, C_{1-6} alkyls-, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl-, C_{1-6} alkenyl, C_{1-6} alkynyl, CF_3CO -, CF_3O C_{1-6} alkylCO-, C_{3-6} cycloalkylCO-, C_{3-6} cycloalkyl- C_{1-4} alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl- C_{1-4} alkyl-, heterocyclyl,


or $-NR^6R^7$ where R^6 is hydrogen or C_{1-4} alkyl, and R^7 is hydrogen, C_{1-4} alkyl, $-CHO$, $-CO_2C_{1-4}$ alkyl or $-COC_{1-4}$ alkyl.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/445 // (C07D 471/04, 221:00, 221:00)		A3	(11) International Publication Number: WO 99/15526
			(43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: PCT/EP98/05904		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 15 September 1998 (15.09.98)			
(30) Priority Data: 9720052.1 19 September 1997 (19.09.97) GB		Published With international search report.	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(88) Date of publication of the international search report: 20 May 1999 (20.05.99)	
(72) Inventors; and (75) Inventors/Applicants (for US only): HARRINGTON, Frank, Peter [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).			
(74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			

(54) Title: N-5,6,7,8-TETRAHYDRO(1,6)NAPHTHYRIDINE-N'-PHENYLUREA DERIVATIVES



(57) Abstract

N-(naphthyridinyl)-N'-phenyl-ureas/thioureas of general formula (I) are useful for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/05904

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D471/04 A61K31/445 //(C07D471/04,221:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 22807 A (NEUROSEARCH AS ;OLESEN SOEREN PETER (DK); MOLDT PETER (DK); PEDERS) 13 October 1994 see ex.1, page 28; ex.1, page 29; ex.3, page 34; ex.6, page 31 ---	1-10
Y	WO 96 39382 A (FUJISAWA PHARMACEUTICAL CO ;ITO KIYOTAKA (JP); SPEARS GLEN W (JP);) 12 December 1996 cited in the application see examples 28-32,63,65 ---	1-10
Y	FR 2 377 377 A (METABIO JOULLIE SA) 11 August 1978 see page 16; example 777 --- -/-	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 1999

Date of mailing of the international search report

18/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/05904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HEINISCH ET AL: "Synthesis of N-aryl-N'-heteroaryl-substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity" ARCHIV DER PHARMAZIE, vol. 330, no. 7, July 1997, pages 207-210, XP002087695 see the whole document ----	1-10
A	EP 0 105 821 A (CORTIAL) 18 April 1984 see page 2 ----	1-10
A	US 4 542 144 A (RASMUSSEN CHRIS R) 17 September 1985 see abstract ----	1-10
A	DE 13 02 662 B (CHEMISCHE WERKE ALBERT) see column 1, line 34 ----	1-10
A	PAVIA M R ET AL: "N-PHENYL-N'-PYRIDINYLUREAS AS ANTICONVULSANT AGENTS1" JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 2, February 1990, pages 854-861, XP000604950 ----	1-10
A	CHEMICAL ABSTRACTS, vol. 73, no. 13, 28 September 1970 Columbus, Ohio, US; abstract no. 64728, XP002095688 see abstract & M. LAZAROVA ET AL.: DOKL. BOLG. AKAD. NAUK., vol. 23, no. 5, 1970, pages 599-602, & ARCH. PHARM., vol. 330, no. 7, 1997, pages 207-210, ----	1-10
A	CHEMICAL ABSTRACTS, vol. 67, no. 21, 20 November 1967 Columbus, Ohio, US; abstract no. 99956, XP002095689 see abstract & N.S. DOBYCHINA ET AL.: IZV. TOMSK. POLITEKH. INST., vol. 151, 1966, pages 85-87, ----	1-10
A	EP 0 556 008 A (SHIONOGI & CO) 18 August 1993 cited in the application see examples 30,34 -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05904

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9422807	A	13-10-1994	AT 175955 T AU 683654 B AU 6537894 A CA 2160128 A DE 69416119 D EP 0693053 A FI 954746 A JP 8510448 T NO 953956 A NZ 265052 A US 5696138 A	15-02-1999 20-11-1997 24-10-1994 13-10-1994 04-03-1999 24-01-1996 17-11-1995 05-11-1996 07-12-1995 19-12-1997 09-12-1997
WO 9639382	A	12-12-1996	NONE	
FR 2377377	A	11-08-1978	GB 1574019 A AU 3233878 A BE 868162 A CA 1104132 A DE 2801187 A FI 780044 A JP 53135945 A LU 79926 A SE 7806467 A US 4252804 A ZA 7800143 A	03-09-1980 19-07-1979 15-12-1978 30-06-1981 20-07-1978 15-07-1978 28-11-1978 09-04-1979 22-06-1979 24-02-1981 27-12-1978
EP 0105821	A	18-04-1984	FR 2533923 A FR 2550198 A CA 1219875 A JP 59088476 A OA 8298 A PT 77429 B US 4499090 A	06-04-1984 08-02-1985 31-03-1987 22-05-1984 31-10-1987 27-02-1986 12-02-1985
US 4542144	A	17-09-1985	NONE	
DE 1302662	B		NONE	
EP 0556008	A	18-08-1993	AT 153023 T CA 2088798 A DE 69310563 D DE 69310563 T DK 556008 T ES 2105099 T GR 3023498 T HU 70035 A JP 5286973 A US 5378848 A US 5461062 A	15-05-1997 23-08-1993 19-06-1997 13-11-1997 09-06-1997 16-10-1997 29-08-1997 28-09-1995 02-11-1993 03-01-1995 24-10-1995

